Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 10/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1474943 | 1.00 | CCR4 (0.42) | CCR4ALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL1474995 | 0.91 | CCR4 (0.37) | CCR4ALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL1474575 | 0.81 | KCNJ1 (0.38) | CCR4ALDH1A1GAAEDNRAKCNJ1 | |
| SCHEMBL29952590 | 0.81 | KCNJ1 (0.38) | CCR4ALDH1A1GAAEDNRAKCNJ1 | |
| SCHEMBL1475275 | 0.81 | GAA (0.37) | CCR4ALDH1A1GAAKCNJ1 | |
| SCHEMBL6057013 | 0.79 | POLB (0.37) | SMN1; SMN2LMNAKCNJ1 | |
| SCHEMBL29955754 | 0.79 | POLB (0.37) | SMN1; SMN2LMNAKCNJ1 | |
| SCHEMBL21274185 | 0.78 | CCR4 (0.42) | CCR4EDNRA | |
| SCHEMBL21274427 | 0.78 | KCNJ1 (0.33) | KCNJ1 | |
| SCHEMBL29862869 | 0.78 | CCR4 (0.42) | CCR4EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428427-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240277706-A1 | METHODS AND COMPOSTITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20230192713-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277706-A1 | METHODS AND COMPOSTITIONS FOR TARGETING PD-L1 | CD274, PDCD1, PDCD1LG2 | CCR4 327/4885ALDH1A1 950/4885GAA 422/4885 |
| US-20230192713-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | CCR4 951/4885ALDH1A1 301/4885GAA 732/4885 |
| US-12428427-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | CCR4 951/4885ALDH1A1 301/4885GAA 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.